For most of us, getting less than seven hours of sleep translates into grogginess, sluggish thinking, and an overwhelming ...

An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

For 2025, Alkermes plans to generate over $200 million in EBITDA while advancing its orexin program, particularly ALKS 2680, which is enrolling Phase 2 studies for narcolepsy. These studies are ...

This important study shows that the activity of hypothalamic hypocretin/orexin neurons (HONs) correlates with body movement over multiple behaviors. Sophisticated techniques and analyses showcase this ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous ...

Neurons that secrete the neuropeptide orexin help mice decide between exercise and snacking. I n neurobiologist Daria ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Goldman Sachs raised the firm’s price target on Alkermes (ALKS) to $32 from $30 and keeps a Buy rating on the shares after its Q4 earnings beat ...

Deutsche Bank (ETR:DBKGn) initiated coverage on Alkermes (NASDAQ:ALKS) shares with a Buy rating and a price target of $40.00.